HRMY Should I Buy
-
$
0.000
0.000(0.000%)
At close0.000(0.000%)Aft-market
ET
Harmony Biosciences Holdings Inc (HRMY) is not a strong buy candidate at this moment for a beginner investor with a long-term strategy. The stock faces significant uncertainties related to its key drug Wakix, with potential generic competition as early as 2026. Additionally, recent financial performance shows declining net income and EPS, despite revenue growth. Technical indicators are bearish, and there are no strong positive catalysts or proprietary trading signals to justify an immediate buy.
The technical indicators are bearish. The MACD is negative and contracting, RSI is neutral at 32.727, and moving averages show a bearish trend (SMA_200 > SMA_20 > SMA_5). The stock is trading below its pivot level of 29.441, with key support at 26.348 and resistance at 32.535.
Hedge funds are significantly increasing their positions in the stock, with a buying increase of 18208.08% over the last quarter. Additionally, revenue grew by 21.12% YoY in Q4 2025.
Analysts have downgraded the stock multiple times recently, citing patent risks and reduced cash flow projections. Financial performance shows a sharp decline in net income (-54.55% YoY) and EPS (-54.12% YoY). Technical indicators are bearish, and no recent news or congress trading data provides support for a positive outlook.
In Q4 2025, revenue increased by 21.12% YoY to $243.78 million. However, net income dropped by 54.55% YoY to $22.49 million, and EPS fell by 54.12% YoY to $0.39. Gross margin slightly declined to 71.88%, down 1.49% YoY.
Analyst sentiment is mixed to negative. UBS lowered the price target to $36 and maintains a Neutral rating. Deutsche Bank downgraded the stock to Hold, citing patent risks, and reduced the price target to $30. BofA lowered the price target to $28 with an Underperform rating. Truist also downgraded the stock to Hold, highlighting substantial risks to the Wakix franchise. Mizuho remains optimistic with an Outperform rating and a price target of $50, but this is an outlier.
